NeoTYPE® Follicular Lymphoma Profile

Follicular lymphoma (FL) is among the most common non-Hodgkin lymphomas worldwide. FL is a fairly heterogeneous disease, with many patients achieving long-term remission and others who will have a remarkably poor outcome. Approximately 90% of FL cases harbor translocations involving BCL2, and the majority of these FL patients will also have one or more additional recurrent gene mutations. Variant follicular lymphomas such as pediatric-type FL, diffuse FL, and primary cutaneous follicle center lymphoma, have been characterized by the absence of BCL2, BCL6 and IRF4 gene rearrangements. It can be difficult to make a definitive diagnosis for these Bcl-2 negative follicular lymphomas.

Recent NGS studies have identified frequent/recurrent gene mutations and rearrangements in follicular lymphoma variants; for example, 70% of pediatric-type FL will have mutations in TNFRSF14 and/or MAP2K1, compared to 9% of BCL2-negative FL in adults. Recent studies have also shown that some gene mutations can serve as prognostic and/or predictive biomarkers, particularly when integrated into composite risk models. Follicular lymphoma with EZH2 mutation may respond to EZH2 inhibitors. Genomic profiling in follicular lymphoma will not only provide diagnostic value, but may also suggest prognostic and therapeutic relevance.

H&E slide (required) plus paraffin block.
Note on FFPE: Paraffin block is preferred. Do not use zinc fixatives. If submitting slides, please use positively-charged slides and 10% NBF fixative. Block and slide identifiers should be clearly written and match exactly with the specimen ID and specimen labeling as noted on the requisition.
Do not use mercury fixatives (B5). Highly acidic or prolonged decalcification processes will not yield sufficient nucleic acid to accurately perform molecular studies.
Note: Test is TNA-based. Please select Extract & Hold - TNA If specimen hold service is desired.